Despite the advances in therapy of cancer, patients with localized (stage II or III) esophageal carcinoma when treated with preoperative chemoradiation have a dismal prognosis (<20% 5-year survival rate). Treatment is associated with dire consequences. Currently, none of the clinical or therapeutic parameters can help to individualize therapy (select certain treatments or avoid others). It is known that response to chemoradiation (as judged by examining the resected specimen) varies. Pathologic complete response (pathCR), defined as the absence of residual cancer, or lack of response (=50% residual cancer or exCRTR) dictates patient outcome. Approximately 25% of patients achieve a pathCR and another 25% exhibit exCRTR. Patients with pathCR survive much longer than those with

Public Health Relevance

The goal of this study (R21/R33) is to study untreated cancer tissue from esophageal cancer patients receiving preoperative chemoradiation to discover if certain molecular biomarker classifiers can help individualize therapy. This is being proposed in two phases: retrospective (R21) and prospective (R33). Only promising findings in the R21 will be validated in the R33 phase. In the R21 phase, the immunohistochemistry (IHC) of NFkB, Shh and Gli-1 as well as relevant drug-related biomarkers will be used to establish a distribution and clinical relevance (pathCR and exCRTR) of biomarker signatures. The IHC methods will be standardized and transferred from the research laboratory to a certified IHC clinical laboratory.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Thurin, Magdalena
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
Other Domestic Higher Education
United States
Zip Code
Harada, Kazuto; Pool Pizzi, Melissa; Baba, Hideo et al. (2018) Cancer stem cells in esophageal cancer and response to therapy. Cancer 124:3962-3964
Harada, Kazuto; Song, Shumei; Ajani, Jaffer A (2018) Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. Oncoscience 5:214-215
Mizrak Kaya, Dilsa; Nogueras-González, Graciela M; Harada, Kazuto et al. (2018) Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol 117:678-684
Harada, Kazuto; Mizrak Kaya, Dilsa; Baba, Hideo et al. (2018) Immune checkpoint blockade therapy for esophageal squamous cell carcinoma. J Thorac Dis 10:699-702
Amlashi, Fatemeh G; Wang, Xuemei; Davila, Raquel E et al. (2018) Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology 95:81-90
Song, Shumei; Xie, Min; Scott, Ailing W et al. (2018) A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer Ther 17:443-454
Sohn, Bo Hwa; Hwang, Jun-Eul; Jang, Hee-Jin et al. (2017) Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res :
Lee, Keun-Wook; Lee, Sung Sook; Hwang, Jun-Eul et al. (2016) Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clin Cancer Res 22:6228-6235
Shiozaki, Hironori; Slack, Rebecca; Sudo, Kazuki et al. (2015) Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology 88:332-6
Shimodaira, Y; Elimova, E; Wadhwa, R et al. (2015) Ramucirumab for the treatment of gastroesophageal cancers. Expert Opin Orphan Drugs 3:737-746

Showing the most recent 10 out of 34 publications